JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells

Gastric cancer is the third most common malignancy in China, with a median 5-year survival of only 20%. Cisplatin has been used in first-line cancer treatment for several types of cancer including gastric cancer. However, patients are often primary resistant or develop acquired resistance resulting...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, W, Chen, Q, Wang, Q, Sun, Y, Wang, S, Li, A, Xu, S, Røe, O D, Wang, M, Zhang, R, Yang, L, Zhou, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649833/
https://www.ncbi.nlm.nih.gov/pubmed/25476899
http://dx.doi.org/10.1038/cddis.2014.517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649833/
https://www.ncbi.nlm.nih.gov/pubmed/25476899
http://dx.doi.org/10.1038/cddis.2014.517

Ejemplares similares